Despite substantial recent advancements in melanoma therapy with T-cell antibodies such as anti-CTLA4 [34] and anti-PD1 [45], or with targeted therapies such as BRAF [35] or MEK [46] inhibitors, adoptive cell therapy with tumor infiltrating lymphocytes still offers the most robust clinical cure rates [47]. The gene discussed is CTLA4; the disease is neoplasm.